Are there clinical benefits with early erythropoietic intervention for chemotherapy‐induced anemia?
- 23 December 2005
- Vol. 106 (1), 223-233
- https://doi.org/10.1002/cncr.21570
Abstract
BACKGROUND In recent years there has been an increasing debate regarding the benefits of initiating erythropoietic treatment in patients with cancer when anemia is still relatively mild. To address this, a systematic review of studies was conducted that answered the following question: Is there a clinical benefit associated with early erythropoietic intervention (hemoglobin ≥ 10 g/dL) for chemotherapy‐induced anemia? METHODS A systematic review of published literature and meeting abstracts was undertaken to identify relevant studies. Data were extracted from studies meeting prespecified eligibility criteria. For outcome measures not associated with significant heterogeneity, summary measures of relative risk associated with early erythropoietic intervention were estimated using the method of Mantel and Haenszel. RESULTS Eleven studies were eligible and were included in the review. Erythropoietic treatment effectively decreased transfusion incidence and the proportion of patients with hemoglobin < 10 g/dL compared with no treatment, with relative risk reductions of 0.50 (95% confidence interval [CI], 0.43, 0.59; 7 studies, P < 0.0001) and 0.40 (95% CI, 0.19, 0.83; 4 studies, P = 0.147), respectively. The findings from both prospective studies and planned subset analyses in which early and late intervention were compared also indicated a reduction in the relative risk of both transfusions and hemoglobin < 10 g/dL after early intervention (0.55 [95% CI, 0.42, 0.73; 5 studies, P < 0.0001] and 0.44 [95% CI, 0.33, 0.57; 2 studies, P < 0.0001], respectively). CONCLUSION Collectively, these findings suggest that optimal clinical benefit from erythropoietic treatment of chemotherapy‐induced anemia may be achieved through early intervention. Cancer 2006. © 2005 American Cancer Society.Keywords
This publication has 29 references indexed in Scilit:
- Measuring inconsistency in meta-analysesBMJ, 2003
- Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapyBritish Journal of Cancer, 2002
- Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of HematologyBlood, 2002
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving ChemotherapyJNCI Journal of the National Cancer Institute, 2002
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001
- Impact of fatigue on quality of life in oncology patientsSeminars in Hematology, 2000
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999
- Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapyMedical Oncology, 1998
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- On the bias of various estimators of the logit and its variance with application to quantal bioassayBiometrika, 1967